0001214659-18-007654.txt : 20181212 0001214659-18-007654.hdr.sgml : 20181212 20181212165504 ACCESSION NUMBER: 0001214659-18-007654 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181210 FILED AS OF DATE: 20181212 DATE AS OF CHANGE: 20181212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Durrant Cameron CENTRAL INDEX KEY: 0001421882 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35798 FILM NUMBER: 181231350 MAIL ADDRESS: STREET 1: 90, FAIRMOUNT ROAD WEST CITY: CALIFON STATE: NJ ZIP: 07830-3330 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HUMANIGEN, INC CENTRAL INDEX KEY: 0001293310 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770557236 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 533 AIRPORT BLVD. STREET 2: SUITE 200 CITY: BURLINGAME STATE: CA ZIP: 94010 BUSINESS PHONE: 650.243.3100 MAIL ADDRESS: STREET 1: 533 AIRPORT BLVD. STREET 2: SUITE 200 CITY: BURLINGAME STATE: CA ZIP: 94010 FORMER COMPANY: FORMER CONFORMED NAME: KALOBIOS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20040609 4 1 marketforms-43503.xml PRIMARY DOCUMENT X0306 4 2018-12-10 0001293310 HUMANIGEN, INC HGEN 0001421882 Durrant Cameron C/O HUMANIGEN, INC. 533 AIRPORT BOULEVARD, SUITE 400 BURLINGAME CA 94010 true true false false Chief Executive Officer Common Stock, $0.001 par value 2018-12-10 4 A false 2500 0.750 A 155083 D Common Stock, $0.001 par value 2018-12-11 4 A false 2500 0.757 A 157583 D The prices reported in Column 4 are weighted average prices. On December 10, 2018, Dr. Durrant purchased 2,500 shares in multiple transactions at prices ranging from $0.711 to $0.809, inclusive. On December 11, 2018, Dr. Durrant purchased an additional 2,500 shares in multiple transactions at prices ranging from $0.749 to $0.761, inclusive. The reporting person undertakes to provide to Humanigen, Inc., any security holder of Humanigen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. /s/ Deborah Brown, Attorney-In-Fact 2018-12-12